Genetic analysis of haptoglobin polymorphisms with cardiovascular disease and type 2 diabetes in the diabetes heart study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Adams, Jeremy N ^a   Cox, Amanda J ^a   Freedman, Barry I ^a   Langefeld, Carl D ^a   Carr, J Jeffrey ^a   Bowden, Donald W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Genetic polymorphism; Haptoglobin; Type 2 diabetes

Indexed keywords

HAPTOGLOBIN; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GENE DUPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC LINKAGE; GENOTYPE; HAPTOGLOBINS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84873512128     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-31     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 2011, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, Centers for Disease Control and Prevention.
2. Bowden DW, Cox AJ, Freedman BI, Hugenschimdt CE, Wagenknecht LE, Herrington D, Agarwal S, Register TC, Maldjian JA, Ng MC, et al. Review of the diabetes heart study (DHS) family of studies: a comprehensively examined sample for genetic and epidemiological studies of type 2 diabetes and its complications. Rev Diabet Stud 2010, 7(3):188-201. 3061609, 21409311.
3. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the american diabetes association; the national heart, lung, and blood institute; the juvenile diabetes foundation international; the national institute of diabetes and digestive and kidney diseases; and the american heart association. Circulation 1999, 100(10):1132-1133.
4. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241(19):2035-2038. 10.1001/jama.1979.03290450033020, 430798.
5. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996, 42(10):1589-1600.
6. Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, Anbinder Y, Lache O, Nakhoul FM, Asaf R, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010, 12(2):293-304. 10.1089/ars.2009.2793, 19659435.
7. Bunn HF, Jandl JH. Exchange of heme among hemoglobin molecules. Proc Natl Acad Sci U S A 1966, 56(3):974-978. 10.1073/pnas.56.3.974, 219955, 5230192.
8. Graversen JH, Madsen M, Moestrup SK. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol 2002, 34(4):309-314. 10.1016/S1357-2725(01)00144-3, 11854028.
9. Schaer CA, Schoedon G, Imhof A, Kurrer MO, Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res 2006, 99(9):943-950. 10.1161/01.RES.0000247067.34173.1b, 17008602.
10. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003, 92(11):1193-1200. 10.1161/01.RES.0000076889.23082.F1, 12750308.
11. Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008, 57(10):2794-2800. 10.2337/db08-0450, 2551691, 18599520.
12. Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, Levy AP. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001, 98(13):3693-3698. 10.1182/blood.V98.13.3693, 11739174.
13. Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP. Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis 2007, 191(1):48-53. 10.1016/j.atherosclerosis.2006.04.032, 16820150.
14. Quaye IK. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008, 102(8):735-742. 10.1016/j.trstmh.2008.04.010, 18486167.
15. Levy AP. Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease. Isr Med Assoc J 2004, 6(5):308-310.
16. Asleh R, Levy AP. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 2005, 1(1):19-28. 10.2147/vhrm.1.1.19.58930, 1993923, 17319095.
17. Spagnuolo MS, Cigliano L, D'Andrea LD, Pedone C, Abrescia P. Assignment of the binding site for haptoglobin on apolipoprotein A-I. J Biol Chem 2005, 280(2):1193-1198.
18. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H, Grijalva V, Hama S, Kozak K, Buga G, et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem 2007, 282(32):23698-23707. 10.1074/jbc.M702163200, 17556366.
19. Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Cardiol 2002, 40(11):1984-1990. 10.1016/S0735-1097(02)02534-2, 12475459.
20. Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, Shochat M, Sulieman A, Reisner SA, Markiewicz W, et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 2005, 54(9):2802-2806. 10.2337/diabetes.54.9.2802, 16123372.
21. Simpson M, Snell-Bergeon JK, Kinney GL, Lache O, Miller-Lotan R, Anbinder Y, Rewers MJ, Levy AP. Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes. Cardiovasc Diabetol 2011, 10:99. 10.1186/1475-2840-10-99, 3231951, 22098782.
22. De Bacquer D, De Backer G, Langlois M, Delanghe J, Kesteloot H, Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 2001, 157(1):161-166. 10.1016/S0021-9150(00)00690-0, 11427216.
23. Levy AP, Larson MG, Corey D, Lotan R, Vita JA, Benjamin EJ. Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort. Atherosclerosis 2004, 172(2):361-365. 10.1016/j.atherosclerosis.2003.10.014, 15019547.
24. Stern MP, Ferrell RE, Rosenthal M, Haffner SM, Hazuda HP. Association between NIDDM, RH blood group, and haptoglobin phenotype. Results from the San Antonio heart study. Diabetes 1986, 35(4):387-391. 10.2337/diabetes.35.4.387, 3082699.
25. Quaye IK, Ababio G, Amoah AG. Haptoglobin 2-2 phenotype is a risk factor for type 2 diabetes in Ghana. J Atheroscler Thromb 2006, 13(2):90-94. 10.5551/jat.13.90, 16733296.
26. Bowden DW, Lehtinen AB, Ziegler JT, Rudock ME, Xu J, Wagenknecht LE, Herrington DM, Rich SS, Freedman BI, Carr JJ, et al. Genetic epidemiology of subclinical cardiovascular disease in the diabetes heart study. Ann Hum Genet 2008, 72(Pt 5):598-610.
27. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of multi-ethnic study of atherosclerosis (MESA) and coronary artery risk development in young adults (CARDIA) study. Radiology 2005, 234(1):35-43. 10.1148/radiol.2341040439, 15618373.
28. Carr JJ, Crouse JR, Goff DC, D'Agostino RB, Peterson NP, Burke GL. Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. AJR Am J Roentgenol 2000, 174(4):915-921.
29. Lange LA, Bowden DW, Langefeld CD, Wagenknecht LE, Carr JJ, Rich SS, Riley WA, Freedman BI. Heritability of carotid artery intima-medial thickness in type 2 diabetes. Stroke 2002, 33(7):1876-1881. 10.1161/01.STR.0000019909.71547.AA, 12105369.
30. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, Kastrati A. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 2002, 48(9):1377-1382.
31. Bento JL, Palmer ND, Zhong M, Roh B, Lewis JP, Wing MR, Pandya H, Freedman BI, Langefeld CD, Rich SS, et al. Heterogeneity in gene loci associated with type 2 diabetes on human chromosome 20q13.1. Genomics 2008, 92(4):226-234. 10.1016/j.ygeno.2008.06.004, 2583938, 18602983.
32. Lewis JP, Palmer ND, Ellington JB, Divers J, Ng MC, Lu L, Langefeld CD, Freedman BI, Bowden DW. Analysis of candidate genes on chromosome 20q12-13.1 reveals evidence for BMI mediated association of PREX1 with type 2 diabetes in European Americans. Genomics 2010, 96(4):211-219. 10.1016/j.ygeno.2010.07.006, 2977534, 20650312.
33. Matarin M, Brown WM, Scholz S, Simon-Sanchez J, Fung HC, Hernandez D, Gibbs JR, De Vrieze FW, Crews C, Britton A, et al. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol 2007, 6(5):414-420. 10.1016/S1474-4422(07)70081-9, 2613843, 17434096.
34. Grant DJ, Maeda N. A base substitution in the promoter associated with the human haptoglobin 2-1 modified phenotype decreases transcriptional activity and responsiveness to interleukin-6 in human hepatoma cells. Am J Hum Genet 1993, 52(5):974-980. 1682050, 8387722.
35. Maeda N. DNA polymorphisms in the controlling region of the human haptoglobin genes: a molecular explanation for the haptoglobin 2-1 modified phenotype. Am J Hum Genet 1991, 49(1):158-166. 1683214, 2063867.
36. Cox SE, Doherty C, Atkinson SH, Nweneka CV, Fulford AJ, Ghattas H, Rockett KA, Kwiatkowski DP, Prentice AM. Haplotype association between haptoglobin (Hp2) and Hp promoter SNP (A-61C) may explain previous controversy of haptoglobin and malaria protection. PLoS One 2007, 2(4):e362. 10.1371/journal.pone.0000362, 1838521, 17426810.
37. Froguel P, Ndiaye NC, Bonnefond A, Bouatia-Naji N, Dechaume A, Siest G, Herbeth B, Falchi M, Bottolo L, Gueant-Rodriguez RM, et al. A genome-wide association study identifies rs2000999 as a strong genetic determinant of circulating haptoglobin levels. PLoS One 2012, 7(3):e32327. 10.1371/journal.pone.0032327, 3293812, 22403646.
38. Hamalainen P, Saltevo J, Kautiainen H, Mantyselka P, Vanhala M. Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study. Cardiovasc Diabetol 2012, 11:116. 10.1186/1475-2840-11-116, 3471017, 23016887.
39. Wobeto VP, Pinho Pda C, Souza JR, Zaccariotto TR, Zonati Mde F. Haptoglobin genotypes and refractory hypertension in type 2 diabetes mellitus patients. Arq Bras Cardiol 2011, 97(4):338-345. 10.1590/S0066-782X2011005000107, 22011804.
40. Ryndel M, Behre CJ, Brohall G, Prahl U, Schmidt C, Bergstrom G, Fagerberg B, Olson FJ. The haptoglobin 2-2 genotype is associated with carotid atherosclerosis in 64-year old women with established diabetes. Clin Chim Acta 2010, 411(7-8):500-504.
41. Nakagawa T, Muramoto Y, Hori M, Mihara S, Marubayashi T, Nakagawa K. A preliminary investigation of the association between haptoglobin polymorphism, serum ferritin concentration and fatty liver disease. Clin Chim Acta 2008, 398(1-2):34-38.